Company
Hutchmed (China) Ltd
LON:HCM
Hutchmed (China) Ltd is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved
60 stories
HUTCHMED Limited kicks off phase III cancer trial
The company’s SULANDA drug candidate will be used to treat neuroendocrine carcinoma
Hutchison China MediTech starts late-stage trial on colorectal cancer drug
Candidate fruquintinib was fast-tracked by the US authorities in June
Hutchison China MediTech starts phase II study for liver cancer treatment
HMPL-453 is a novel small molecule inhibitor targeting certain receptors that drive tumour growth
Investments and investor services
FTSE 100 closes lower but BP top gainer after Q2 results beat expectations
The FTSE 100 index closed 39.84 points lower on the day at 7,646, while the midcap FTSE 250 index plunged almost 112 points to close at 19,774
Archive
Greggs on a roll after vegan success but can it keep up the momentum?
Greggs, Reckitt Benckiser and Provident Financial are among the companies reporting results on Tuesday
Archive
Week ahead preview: Lloyds, Barclays, RBS, BT Group, BoE and US Fed
It will be a busy week for markets with a barrage of corporate earnings and interest rates decisions from the Bank of England and the US Federal Reserve.
Investments and investor services
FTSE 100 clings on to gains as rumours swirl of visit by Theresa May to the Last Chance saloon in Strasbourg
Straight from the horse's mouth? Not really. It was the deputy head of the Irish government, Simon Coveney, who confirmed that Theresa May will fly to Strasbourg this evening “to try to finalise an agreement, if that’s possible”.
Hutchison Chi-Med sheds £900mln as lung cancer trial disappoints
In a study of 527 patients in China, fruquintinib slowed the disease but failed to improve survival rates
Hutchison ChinaMediTech's colorectal cancer treatment approved in China
Colorectal cancer is the second most common cancer type in China, with about 380,000 new cases per year
Hutchison Chi-Med expects first drug launch by year end
The AIM-listed drug developer has applied for approval in China in advanced colorectal cancer
FTSE 100 closes higher, boosted by earnings and weaker pound
In London, FTSE 100 added over 38 points to finish at 7,701 - that was up on the week too, marginally - by 0.29%.
Archive
BT investors 'flying blind' as it reports first quarter results without net adds
Jefferies reckons the key focus for BT's quarterly results will be on the business and public sector division following a poor performance last year
Hutchison China Meditech starts US proof-of-concept trial for key cancer drug
The Phase Ib/II study is for people suffering from pancreatic neuroendocrine tumours (NET) and biliary tract cancer (BTC)
Archive
Apres moi le deluge: Flood of blue chip results to dominate in coming week, including BT Group
Over the five sessions in the Week Ahead, around 20% of the FTSE 100 index will report results or issue a trading update, with about half that number due on Thursday alone
Archive
Momentum investing: Use the Force, Luke
A lot of academic research suggests a momentum investing strategy outperforms the market. John Harrington attempts to concoct a lazy person's momentum investing system.
Hutchison China Meditech looks to first drug approval this year
Simon To, chairman, said: "In our Innovation Platform, we have progressed our deep portfolio of eight clinical drug candidates"
Investments and investor services
FTSE 100 can’t hold gains and closes in red as sterling firms
Britain's blue-chip benchmark closed down over nine points, or 0.13% to 7,214..
Archive
Banks to dominate another busy earnings week, including numbers from HSBC and RBS
Week ahead: HSBC, Royal Bank of Scotland, Royal Dutch Shell, Next, Centrica, Shire, US jobs, Bank of England policy meeting ...
Hutchison China MediaTech reports record 2016 revenue as commercial sales rise
The biopharma company said it has made progress on the development of several cancer treatments
Archive
Antofagasta closing in on a feasibility study of expansion of Los Pelambres
Big names reporting include Antofagasta, Hikma and Robert Walters.
Hutchison China MediTech kicks off first human trial for potential new cancer drug
HMPL-453 targets fibroblast growth factor receptors, which are central to several biological processes
Hutchison China MediTech half year charts big progress
The group has seven candidates being tested across 25 clinical trials, including four pivotal Phase III studies
Archive
SafeCharge in safe hands
Hutchison China Meditech starts trials of blood cancer drug
Hutchison MediPharma has begun the first-in-human phase one clinical trial of HMPL-689 in Australia
Genel Energy a highlight as stocks advance
A proposed buy-back of bonds and a revised reserves estimate has done wonders for Genel's share price, but airing of dirty laundry has hit Fastjet
Archive
Beaufort Securities Breakfast Alert
Market opening: The FTSE-100 is expected to start this morning's session around 50-points higher. New York: Wall Street ended in the green as robust data on ISM manufacturing and construction spending in the US lifted investor sentiment. Ad
Investments and investor services
Risers & Fallers: AA, Travis Perkins, Shire, ServicePower and Pearson...
Below are the main news-driven share price movements at 4pm.
Risers & Fallers: Anglo American, Minds + Machines, UTV Media, Telit Communications and more...
Below are the main news-driven share price movements at 1pm.
Investments and investor services
London shares end week on high; Shire up on M&A talk
The FTSE100 pushed on throughout the afternoon, ending around 40 points higher to 6,378.
Investments and investor services
Risers & Fallers: Hutchison China MediTech, DJI Holdings, Sefton Resources, PeerTV and more...
Below are the main news-driven share price movements at 4pm.